Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Scholar Rock Holding (SRRK) and Nuvation Bio (NUVB)

Tipranks - Wed Mar 4, 10:30AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Scholar Rock Holding (SRRKResearch Report) and Nuvation Bio (NUVBResearch Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Scholar Rock Holding (SRRK)

H.C. Wainwright analyst Andres Y. Maldonado maintained a Buy rating on Scholar Rock Holding today and set a price target of $58.00. The company’s shares closed last Tuesday at $46.01, close to its 52-week high of $46.98.

According to TipRanks.com, Maldonado is a 5-star analyst with an average return of 49.4% and a 55.6% success rate. Maldonado covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Zentalis Pharmaceuticals, and Monopar Therapeutics Inc. ;'>

Currently, the analyst consensus on Scholar Rock Holding is a Strong Buy with an average price target of $53.50.

See the top stocks recommended by analysts >>

Nuvation Bio (NUVB)

The company’s shares closed last Tuesday at $4.33.

According to TipRanks.com, Roy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.0% and a 30.9% success rate. Roy covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Bicara Therapeutics Inc. ;'>

Currently, the analyst consensus on Nuvation Bio is a Strong Buy with an average price target of $12.00, a 149.5% upside from current levels. In a report released yesterday, RBC Capital also maintained a Buy rating on the stock with a $13.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.